Mostrar el registro sencillo del ítem

Artículo

dc.creatorPortillo Calderón, Inés Maríaes
dc.creatorOrtiz Padilla, Miriames
dc.creatorRodríguez Martínez, José Manueles
dc.creatorDe Gregorio Iaria, Belénes
dc.creatorBlázquez, Jesúses
dc.creatorRodríguez-Baño, Jesúses
dc.creatorPascual Hernández, Álvaroes
dc.creatorDocobo Pérez, Fernandoes
dc.date.accessioned2024-05-27T09:51:57Z
dc.date.available2024-05-27T09:51:57Z
dc.date.issued2020
dc.identifier.citationPortillo Calderón, I.M., Ortiz Padilla, M., Rodríguez Martínez, J.M., De Gregorio Iaria, B., Blázquez, J., Rodríguez-Baño, J.,...,Docobo Pérez, F. (2020). Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli. Journal of Antimicrobial Chemotherapy, Volumen: 75 Número: 8 Páginas: 2066 - 2075 (8), 2066-2075. https://doi.org/10.1093/jac/dkaa131.
dc.identifier.issn0305-7453es
dc.identifier.issn1460-2091es
dc.identifier.urihttps://hdl.handle.net/11441/159029
dc.description.abstractObjectives: To explore the effect of combining defects in DNA repair systems with the presence of fosfomycin-resistant mechanisms to explain the mechanisms underlying fosfomycin heteroresistance phenotypes in Enterobacteriaceae. Materials and methods: We used 11 clinical Escherichia coli isolates together with isogenic single-gene deletion mutants in the E. coli DNA repair system or associated with fosfomycin resistance, combined with double-gene deletion mutants. Fosfomycin MICs were determined by gradient strip assay (GSA) and broth microdilution (BMD). Mutant frequencies for rifampicin (100 mg/L) and fosfomycin (50 and 200 mg/L) were determined. Using two starting inocula, in vitro fosfomycin activity was assessed over 24 h in growth (0.5-512 mg/L) and time-kill assays (64 and 307 mg/L). Results: Strong and weak mutator clinical isolates and single-gene deletion mutants, except for ΔuhpT and ΔdnaQ, were susceptible by GSA. By BMD, the percentage of resistant clinical isolates reached 36%. Single-gene deletion mutants showed BMD MICs similar to those for subpopulations by GSA. Strong mutators showed a higher probability of selecting fosfomycin mutants at higher concentrations. By combining the two mechanisms of mutation, MICs and ranges of resistant subpopulations increased, enabling strains to survive at higher fosfomycin concentrations in growth monitoring assays. In time-kill assays, high inocula increased survival by 37.5% at 64 mg/L fosfomycin, compared with low starting inocula. Conclusions: The origin and variability of the fosfomycin heteroresistance phenotype can be partially explained by high mutation frequencies together with mechanisms of fosfomycin resistance. Subpopulations should be considered until clinical meaning is established.es
dc.formatapplication/pdfes
dc.format.extent10 p.es
dc.language.isoenges
dc.publisherOxford University Presses
dc.relation.ispartofJournal of Antimicrobial Chemotherapy, Volumen: 75 Número: 8 Páginas: 2066 - 2075 (8), 2066-2075.
dc.subjectHigh mutation-rateses
dc.subjectFrequencyes
dc.subjectEmergencees
dc.subjectMutatorses
dc.subjectBroth microdilutiones
dc.subjectSusceptibilityes
dc.titleContribution of hypermutation to fosfomycin heteroresistance in Escherichia colies
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/acceptedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Microbiologíaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDPI10/02021es
dc.relation.projectIDREIPI RD12/0015/0010es
dc.relation.projectIDREIPI RD16/0016/0001es
dc.relation.publisherversionhttps://academic.oup.com/jac/article/75/8/2066/5842235es
dc.identifier.doi10.1093/jac/dkaa131es
dc.journaltitleJournal of Antimicrobial Chemotherapyes
dc.publication.volumenVolumen: 75 Número: 8 Páginas: 2066 - 2075es
dc.publication.issue8es
dc.publication.initialPage2066es
dc.publication.endPage2075es
dc.contributor.funderInstituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases - European Development Regional Fund 'A way to achies
dc.contributor.funderPlan Nacional de I+D+i 2013-2016es
dc.description.awardwinningPremio Mensual Publicación Científica Destacada de la US. Facultad de Medicina

FicherosTamañoFormatoVerDescripción
Contribution of hypermutation ...1.071MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.